ATE411996T1 - Kondensierte azolpyrimidinderivate - Google Patents

Kondensierte azolpyrimidinderivate

Info

Publication number
ATE411996T1
ATE411996T1 AT03788908T AT03788908T ATE411996T1 AT E411996 T1 ATE411996 T1 AT E411996T1 AT 03788908 T AT03788908 T AT 03788908T AT 03788908 T AT03788908 T AT 03788908T AT E411996 T1 ATE411996 T1 AT E411996T1
Authority
AT
Austria
Prior art keywords
azolpyrimidine
condensed
derivatives
condensed azolpyrimidine
azolpyrimidine derivatives
Prior art date
Application number
AT03788908T
Other languages
English (en)
Inventor
Mitsuyuki Shimada
Toshiki Murata
Kinji Fuchikami
Hideki Tsujishita
Naoki Omori
Issei Kato
Mami Miura
Klaus Urbahns
Florian Gantner
Kevin Bacon
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of ATE411996T1 publication Critical patent/ATE411996T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT03788908T 2002-09-30 2003-09-18 Kondensierte azolpyrimidinderivate ATE411996T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021861 2002-09-30

Publications (1)

Publication Number Publication Date
ATE411996T1 true ATE411996T1 (de) 2008-11-15

Family

ID=32039115

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08075839T ATE511510T1 (de) 2002-09-30 2003-09-18 Kondensierte azol-pyrimidin-derivate
AT03788908T ATE411996T1 (de) 2002-09-30 2003-09-18 Kondensierte azolpyrimidinderivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08075839T ATE511510T1 (de) 2002-09-30 2003-09-18 Kondensierte azol-pyrimidin-derivate

Country Status (32)

Country Link
US (2) US7511041B2 (de)
EP (2) EP1549652B1 (de)
JP (1) JP4790266B2 (de)
KR (1) KR101059652B1 (de)
CN (1) CN100384846C (de)
AR (2) AR041426A1 (de)
AT (2) ATE511510T1 (de)
AU (1) AU2003293310B2 (de)
BR (1) BRPI0314830B8 (de)
CA (1) CA2499134C (de)
CY (2) CY1109790T1 (de)
DE (1) DE60324296D1 (de)
DK (2) DK1549652T3 (de)
EC (2) ECSP055768A (de)
ES (2) ES2367141T3 (de)
HR (2) HRP20131159B1 (de)
IL (1) IL166855A (de)
MA (1) MA27483A1 (de)
MX (1) MXPA05001808A (de)
MY (1) MY140756A (de)
NO (1) NO331457B1 (de)
NZ (1) NZ539062A (de)
PE (1) PE20050089A1 (de)
PL (1) PL226562B1 (de)
PT (2) PT1549652E (de)
RU (1) RU2326881C9 (de)
SI (2) SI2042504T1 (de)
TW (1) TWI327570B (de)
UA (1) UA82205C2 (de)
UY (1) UY28001A1 (de)
WO (1) WO2004029055A1 (de)
ZA (1) ZA200503306B (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ZA200601765B (en) 2003-08-29 2008-03-26 Mitsui Chemicals Inc Insecticide for agricultural or horticultural use and method of use thereof
EP1761540B1 (de) 2004-05-13 2016-09-28 Icos Corporation Chinazolinone als inhibitoren der humanen phosphatidylinosit-3-kinase delta
RU2403258C2 (ru) 2004-10-07 2010-11-10 Бёрингер Ингельхайм Интернациональ Гмбх Тиазолилдигидроиндазолы
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EP2360278A1 (de) 2005-04-14 2011-08-24 Trustees Of Boston University Diagnose für Lungenerkrankungen mittels Klassenvorhersage
WO2007016979A2 (en) * 2005-07-29 2007-02-15 4Sc Ag NOVEL HETEROCYCLIC NF-κB INHIBITORS
EP1999472A2 (de) 2006-03-09 2008-12-10 The Trustees Of Boston University Diagnose- und prognoseverfahren für lungenerkrankungen mittels genexpressionsprofilen aus nasenepithelzellen
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
CN101479274B (zh) * 2006-04-26 2013-06-12 霍夫曼-拉罗奇有限公司 药用化合物
WO2008064244A2 (en) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP1953163A1 (de) 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinon-Derivate als PI3-Kinases Inhibitoren
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
EP2217590A4 (de) * 2007-09-17 2011-12-14 Glaxosmithkline Llc Pyridopyrimidinderivate als pi3-kinase-inhibitoren
AU2008302076B2 (en) * 2007-09-19 2015-06-11 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
JP5620275B2 (ja) * 2008-01-14 2014-11-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン誘導体類
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
US20090227575A1 (en) * 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
EP2277881A4 (de) * 2008-04-18 2011-09-07 Shionogi & Co Heterocyclische verbindung mit inhibierender wirkung auf p13k
EP2303890A4 (de) * 2008-06-19 2012-04-11 Progenics Pharm Inc Inhibitoren von phosphatidylinosit-3-kinase
EP2168583A1 (de) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Verwendungen von substituierten 2,3-Dihydroimidazo[1,2-c]quinazolinen zur Behandlung von Myelom
EP2168582A1 (de) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Kombinationen aus substituierten 2,3-dihydroimidazo[1,2-c]chinazolinen
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
EP2364983B1 (de) * 2008-11-11 2013-10-23 Jeil Pharmaceutical Co., Ltd. Neues tricyclisches derivat und pharmazeutisch unbedenkliche salze davon, verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20160091440A (ko) 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
SG175259A1 (en) 2009-04-20 2011-11-28 Gilead Calistoga Llc Methods of treatment for solid tumors
AR076435A1 (es) * 2009-04-30 2011-06-08 Glaxo Group Ltd Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
AU2010276160A1 (en) 2009-07-21 2012-02-09 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
RU2595718C2 (ru) * 2009-09-09 2016-08-27 Селджен Авиломикс Рисерч,Инк. Ингибиторы pi3-киназы и их применение
PE20130191A1 (es) 2010-04-16 2013-02-21 Bayer Ip Gmbh Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2621486A1 (de) 2010-10-01 2013-08-07 Bayer Intellectual Property GmbH Substituierte n-(2-arylamino)arylsulfonamid-haltige kombinationen
CN103370320B (zh) * 2010-11-11 2016-04-27 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
US9730943B2 (en) 2010-11-11 2017-08-15 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (de) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituierte 2,3-Dihydroimidazo[1,2-c]chinazolinsalze
EA025407B1 (ru) 2012-03-05 2016-12-30 Джилид Калистога Ллс Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
WO2014186036A1 (en) 2013-03-14 2014-11-20 Allegro Diagnostics Corp. Methods for evaluating copd status
RU2015143437A (ru) 2013-03-15 2017-04-27 Дженентек, Инк. Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
UA119537C2 (uk) 2013-04-08 2019-07-10 Байєр Фарма Акцієнгезелльшафт ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
PE20161063A1 (es) 2013-05-01 2016-10-22 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
WO2015027431A1 (en) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
NZ720867A (en) 2013-12-20 2018-01-26 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
CN114606309A (zh) 2014-11-05 2022-06-10 威拉赛特公司 使用机器学习和高维转录数据的诊断系统和方法
EP3018131A1 (de) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthese von Copanlisib sowie dessen Dihydrochloridsalz
EP3018127A1 (de) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthese von Copanlisib sowie dessen Dihydrochloridsalz
CA2978830A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CA3016584A1 (en) * 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3219329A1 (de) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Kombinationen von copanlisib
EP4180531A3 (de) 2016-05-12 2023-08-23 Trustees of Boston University Genexpressionssignatur des nasenepithels und klassifikator zur vorhersage von lungenkrebs
WO2018009915A1 (en) 2016-07-08 2018-01-11 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CA3045041A1 (en) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
WO2018153980A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
EP3645005A1 (de) 2017-06-28 2020-05-06 Bayer Consumer Care AG Kombination eines pi3k-hemmers mit einem androgen-rezeptor-antagonisten
CN111278430A (zh) 2017-09-08 2020-06-12 拜耳制药股份公司 库潘尼西制剂
EP3498266A1 (de) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulierungen von copanlisib
AU2018338098B2 (en) * 2017-09-20 2024-02-22 Abm Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
WO2019073031A1 (en) 2017-10-13 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) POLYTHERAPY OF PANCREATIC CANCER
US12000833B2 (en) 2017-11-23 2024-06-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Marker for predicting the sensitivity to PI3K inhibitors
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
CN112789279B (zh) * 2018-07-27 2023-09-29 上海翰森生物医药科技有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN109053554B (zh) * 2018-08-01 2020-07-28 江苏八巨药业有限公司 一种使用催化剂合成3-乙酰吡啶的方法
WO2020043617A1 (en) 2018-08-28 2020-03-05 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (de) 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Kombination von atr-kinase-inhibitoren mit 2,3-dihydroimidazo[1,2-c]chinazolinverbindungen
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
CN114621236B (zh) * 2022-04-25 2024-06-18 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
NZ234186A (en) * 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
CN1033644C (zh) * 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
FI970588L (fi) 1994-08-12 1997-04-11 Pro Neuron Inc Menetelmät verenmyrkytyksen tai tulehdussairauksien hoitamiseksi oksipuriininukleosideillä
WO1997027177A2 (en) * 1996-01-29 1997-07-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivatives, their preparation and their use as adenosine receptor antagonists
US5932584A (en) * 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
DK2223922T3 (en) 2000-04-25 2016-06-06 Icos Corp Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives

Also Published As

Publication number Publication date
JP2006508063A (ja) 2006-03-09
TWI327570B (en) 2010-07-21
PL226562B1 (pl) 2017-08-31
PE20050089A1 (es) 2005-04-20
CA2499134A1 (en) 2004-04-08
US8129386B2 (en) 2012-03-06
KR101059652B1 (ko) 2011-08-25
ES2367141T3 (es) 2011-10-28
BRPI0314830B8 (pt) 2021-05-25
CY1112174T1 (el) 2015-12-09
NO331457B1 (no) 2012-01-09
MY140756A (en) 2010-01-15
HRP20131159B1 (hr) 2019-11-01
BRPI0314830B1 (pt) 2018-03-27
ECSP11005768A (es) 2011-03-31
WO2004029055A1 (en) 2004-04-08
SI2042504T1 (sl) 2011-10-28
HRP20050375B1 (hr) 2014-03-14
MA27483A1 (fr) 2005-08-01
ATE511510T1 (de) 2011-06-15
DK2042504T3 (da) 2011-09-19
EP1549652B1 (de) 2008-10-22
BR0314830A (pt) 2005-08-16
UA82205C2 (en) 2008-03-25
US20060128732A1 (en) 2006-06-15
TW200413379A (en) 2004-08-01
CA2499134C (en) 2011-12-20
CN100384846C (zh) 2008-04-30
EP2042504B1 (de) 2011-06-01
HK1084393A1 (zh) 2006-07-28
PT2042504E (pt) 2011-09-07
HRP20050375A2 (en) 2006-05-31
AU2003293310B2 (en) 2010-04-01
US20090270388A1 (en) 2009-10-29
ZA200503306B (en) 2006-07-26
ES2312843T3 (es) 2009-03-01
RU2326881C2 (ru) 2008-06-20
EP1549652A1 (de) 2005-07-06
DK1549652T3 (da) 2009-02-23
RU2005113165A (ru) 2005-10-10
US7511041B2 (en) 2009-03-31
SI1549652T1 (sl) 2009-04-30
PT1549652E (pt) 2008-12-15
RU2326881C9 (ru) 2009-04-10
ECSP055768A (es) 2005-08-11
AR072458A2 (es) 2010-09-01
CY1109790T1 (el) 2014-09-10
KR20050067404A (ko) 2005-07-01
UY28001A1 (es) 2004-04-30
AU2003293310A1 (en) 2004-04-19
JP4790266B2 (ja) 2011-10-12
EP2042504A1 (de) 2009-04-01
CN1688582A (zh) 2005-10-26
DE60324296D1 (de) 2008-12-04
PL375935A1 (en) 2005-12-12
HRP20131159A2 (hr) 2014-05-23
NZ539062A (en) 2007-05-31
NO20052076L (no) 2005-04-27
AR041426A1 (es) 2005-05-18
IL166855A (en) 2014-05-28
MXPA05001808A (es) 2005-08-16

Similar Documents

Publication Publication Date Title
DE60324296D1 (de) Kondensierte azolpyrimidinderivate
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate
ATE450506T1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
DK2248807T3 (da) N-Phenyl-2-pyrimidinaminderivater
ATE427876T1 (de) Luftkissenboot
NO20044046L (no) Substituerte hydroksyetylaminer
DE50311918D1 (de) Nockenwellenversteller
DE50302271D1 (de) Kondensor
ATE349458T1 (de) Etonogestrelester
DE60307512D1 (de) 3h-chinazoline -4-on derivaten
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
ATA1572002A (de) Managementspleisskassette
ATE457299T1 (de) 4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
ATA4142004A (de) Trägerverbau
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
ATE396192T1 (de) N-sulfonylaminothiazole
ATE350379T1 (de) Substituierte benzdioxepine
IS7906A (is) Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls
ATA16872002A (de) Zwischenstück
AT5889U3 (de) Brennholzspleisser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1549652

Country of ref document: EP

EEIH Change in the person of patent owner